Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet

• Publication date

  2016-07-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(16)30363-4PMID 27287832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.

  2016cited by this paper
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.

  2015cited by this paper
• Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

  2015cited by this paper
• Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice.

  2015cited by this paper
• Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts

  2015cited by this paper
• Evolutionary medicine and bone loss in chronic inflammatory diseases--A theory of inflammation-related osteopenia.

  2015cited by this paper
• The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

  2015cited by this paper
• Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis

  2015cited by this paper
• Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

  2015cited by this paper
• FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

  2014cited by this paper
• Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial

  2014cited by this paper
• Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

  2014cited by this paper
• Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

  2014cited by this paper
• A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

  2014cited by this paper
• Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis

  2013cited by this paper
• Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

  2013cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

  2013cited by this paper
• Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study

  2013cited by this paper
• Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

  2013cited by this paper
• Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

  2013cited by this paper
• Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

  2013cited by this paper
• Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

  2013cited by this paper
• Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis

  2013cited by this paper
• Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

  2012cited by this paper
• Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.

  2012cited by this paper
• Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

  2012cited by this paper
• A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

  2012cited by this paper
• Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

  2012cited by this paper
• Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study

  2011cited by this paper
• Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

  2011cited by this paper
• Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review

  2011cited by this paper
• Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

  2010cited by this paper
• Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

  2010cited by this paper
• Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

  2010cited by this paper
• UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha,

  2010cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• The Minimally Important Difference for the Health Assessment Questionnaire in Rheumatoid Arthritis Clinical Practice Is Smaller Than in Randomized Controlled Trials

  2009cited by this paper
• Measures of Rheumatoid Arthritis Disease Activity

  2009cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

  2007cited by this paper
• Consensus Dutch Health Assessment Questionnaire

  2006cited by this paper
• Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro

  2005cited by this paper
• A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

  2005cited by this paper
• Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

  2005cited by this paper
• Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence.

  2002cited by this paper
• How to read radiographs according to the Sharp/van der Heijde method.

  1999cited by this paper
• How to read radiographs according to the Sharp/van der Heijde method.

  1999cited by this paper
• Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

  1998cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.

  2026cites this paper
• Impact of Disease Duration and Onset Pattern on Treatment Delays and Progression of Rheumatoid Arthritis: Insights From a Pakistani Cohort.

  2025cites this paper
• Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis

  2025cites this paper
• Treating connective tissue disease-associated interstitial lung disease – think outside the box: a perspective

  2025cites this paper
• Role of Interleukin-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Focus on the JAK/STAT Pathway and Macrophage Polarization

  2025cites this paper
• Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis

  2025cites this paper
• Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress

  2025cites this paper
• Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis

  2025cites this paper
• Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data

  2025cites this paper
• Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects

  2025cites this paper
• Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial.

  2025cites this paper
• Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients.

  2025cites this paper
• Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model‐Based Meta‐Analysis

  2025cites this paper
• Integrating Primary Care and Specialized Therapies in Rheumatoid Arthritis: Optimizing Recognition, Management, and Referral Practices

  2025cites this paper
• 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis.

  2024cites this paper
• Predictors of Drug Retention and Survival Rate of bDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience

  2024cites this paper
• Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.

  2024cites this paper
• The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.

  2024cites this paper
• Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis

  2024cites this paper
• Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

  2024cites this paper
• CONTExT-RA: a cross-sectional study evaluating disease activity, quality of life and the socio-demographic profile of Irish patients with rheumatoid arthritis

  2024cites this paper
• Human genetic evidence to inform clinical development of interleukin-6 signaling inhibition for abdominal aortic aneurysm

  2024cites this paper
• Human genetic evidence to inform clinical development of interleukin-6 signaling inhibition for abdominal aortic aneurysm

  2024cites this paper
• Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.

  2024cites this paper
• Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

  2024cites this paper
• What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?

  2024cites this paper
• Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide

  2024cites this paper
• Initial Treatment with Biological Therapy in Rheumatoid Arthritis

  2023influential citation
• Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

  2023cites this paper
• Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.

  2023cites this paper
• Efficacy and safety of Duhuo-Jisheng decoction in rheumatoid arthritis: A systematic review and meta-analysis of 42 randomized controlled trials

  2023cites this paper
• The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

  2023cites this paper
• Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients

  2023cites this paper
• Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

  2023cites this paper
• What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis

  2023cites this paper
• Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis

  2023cites this paper
• Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8

  2023cites this paper
• CAR-T Cell Therapy: the Efficacy and Toxicity Balance

  2023cites this paper
• The Gap in Knowledge about Tapering Targeted Therapy being used as Monotherapy in Rheumatoid Arthritis: A Systematic Review.

  2023cites this paper
• Mechanisms of Peripheral and Central Sensitization in Osteoarthritis Pain

  2023cites this paper
• Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

  2023cites this paper
• Non‐erythropoiesis stimulating agent, non‐iron therapies for the management of anemia: A scoping review

  2023cites this paper
• Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα/gp130 hexameric signaling complex formation

  2022cites this paper
• Randomized clinical trials on the efficacy and safety of tocilizumab in subjects with rheumatoid arthritis: a systematic review.

  2022cites this paper
• Highly effective rheumatoid arthritis therapy by peptide-promoted nanomodification of mesenchymal stem cells.

  2022cites this paper
• Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis

  2022cites this paper
• Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?

  2022cites this paper
• Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice

  2022cites this paper
• Neues zu Therapiestrategien bei der rheumatoiden Arthritis

  2022cites this paper
• Interleukin-6 in Spinal Cord Injury: Could Immunomodulation Replace Immunosuppression in the Management of Acute Traumatic Spinal Cord Injuries?

  2022cites this paper
• Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies

  2022cites this paper
• Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis

  2022cites this paper
• Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials

  2022cites this paper
• Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.

  2022cites this paper
• Janus Kinase Inhibitor Selectivity in Rheumatoid Arthritis: Where Do We Stand?

  2022influential citation
• Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

  2022cites this paper
• Current status and prospects of IL-6–targeting therapy

  2022cites this paper
• A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

  2022cites this paper
• Systematic review and meta-analysis on the efficacy of methotrexate in rheumatoid arthritis.

  2021influential citation
• Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme

  2021cites this paper
• Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China

  2021cites this paper
• Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.

  2021cites this paper
• Glukokortikoidfreie und glukokortikoidarme Therapie der rheumatoiden Arthritis

  2021cites this paper
• Interleucina-6

  2021cites this paper
• OP0021 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN EARLY RHEUMATOID ARTHRITIS PATIENTS RESPONDING TO TOCILIZUMAB

  2021cites this paper
• Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies

  2021cites this paper
• HOMEOBOX D TRANSCRIPTION FACTORS SHAPE DIFFERENTIAL JOINT ENVIRONMENT BETWEEN ANTERIOR FINGER JOINTS AND THUMB

  2021cites this paper
• Potential Effects of Coronaviruses on the Liver: An Update

  2021cites this paper
• Facteurs prédictifs de poussée de polyarthrite rhumatoïde après arrêt du méthotrexate dans un traitement combiné avec du tocilizumab

  2021cites this paper
• Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy?

  2021cites this paper
• A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis

  2021cites this paper
• Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis

  2021cites this paper
• Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study

  2021cites this paper
• MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients

  2021cites this paper
• Downregulation of miR‐98‐5p expression induces interleukin‐6 expression in rheumatoid fibroblast‐like synoviocytes

  2021cites this paper
• Glukokortikoidfreie und glukokortikoidarme Therapie der rheumatoiden Arthritis

  2021cites this paper
• Unravelling the Cost of Biological Strategies in Rheumatoid Arthritis: A Kaleidoscope of Methodologies, Interpretations, and Interests

  2021cites this paper
• What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?

  2021cites this paper
• IL-6R blockade by chikusetsusaponin IVa butyl ester inhibits Th17 cell differentiation and ameliorates collagen-induced arthritis

  2021cites this paper
• Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

  2021cites this paper
• Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.

  2021cites this paper
• If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study

  2021cites this paper
• Design and analysis considerations for first treatment escalation in clinical trials.

  2021cites this paper
• Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis

  2021cites this paper
• Prevalence and predictors of adverse events with methotrexate mono- and combination- therapy for rheumatoid arthritis: a systematic review.

  2021cites this paper
• Complex Machine-Learning Algorithms and Multivariable Logistic Regression on Par in the Prediction of Insufficient Clinical Response to Methotrexate in Rheumatoid Arthritis

  2021cites this paper
• Prevention and Cure: The major Unmet needs in the Management of RA

  2021cites this paper
• Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

  2021cites this paper
• Au@polydopamine nanoparticles/tocilizumab composite as efficient scavengers of oxygen free radicals for improving the treatment of rheumatoid arthritis.

  2021cites this paper
• Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis

  2021cites this paper
• Targetable pathogenic mechanisms in nasal polyposis

  2021cites this paper
• Systematic review and meta analysis Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review

  2021cites this paper
• Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials

  2020influential citation
• Tocilizumab can efficiently prevent bone destruction in patients with recent-onset rheumatoid arthritis

  2020cites this paper
• Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis

  2020cites this paper
• Protocol for Systematic Review and Meta-Analysis on the Efficacy and Safety of Tocilizumab

  2020cites this paper
• Why remission is not enough: underlying disease mechanisms in RA that prevent cure

  2020cites this paper
• Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials

  2020cites this paper
• Tailoring biologic therapy for real-world rheumatoid arthritis patients

  2020cites this paper